The increased gastroprotective effect of pioglitazone in cholestatic rats: Role of nitric oxide and tumour necrosis factor alpha

International Journal of Experimental Pathology

Volumn 95, Issue 1, 2014, Pages 78-85

  Moezi, Leila ^a,b   Janahmadi, Zeinab ^a   Amirghofran, Zahra ^a   Nekooeian, Ali Akbar ^a   Dehpour, Ahmad R ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cholestasis; Gastric ulcers; Nitric oxide; Pioglitazone; Rat; Tumour necrosis factor alpha

Indexed keywords

ALCOHOL; AMINOGUANIDINE; BILIRUBIN; INTERLEUKIN 1BETA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PIOGLITAZONE; SOLVENT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CHRONIC DRUG ADMINISTRATION; COMMON BILE DUCT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; LIGATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SHAM PROCEDURE; STOMACH MUCOSA LESION; STOMACH PROTECTION; STOMACH ULCER;

CHOLESTASIS; GASTRIC ULCERS; NITRIC OXIDE; PIOGLITAZONE; RAT; TUMOUR NECROSIS FACTOR ALPHA;

ANIMALS; CHOLESTASIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; INTERLEUKIN-1BETA; MALE; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; STOMACH ULCER; THIAZOLIDINEDIONES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84892961259     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12067     Document Type: Article

References (49)

1. Akiba Y., Nakamura M., Mori M. et al. (1998) Inhibition of inducible nitric oxide synthase delays gastric ulcer healing in the rat. J. Clin. Gastroenterol. 27(Suppl 1), S64-S73.
2. Allami N., Javadi-Paydar M., Rayatnia F. et al. (2011) Suppression of nitric oxide synthesis by L-NAME reverses the beneficial effects of pioglitazone on scopolamine-induced memory impairment in mice. Eur. J. Pharmacol. 650, 240-248.
3. Assimakopoulos S.F., Scopa C.D., Vagianos C.E. (2007) Pathophysiology of increased intestinal permeability in obstructive jaundice. World J. Gastroenterol. 13, 6458-6464.
4. Bagi Z., Koller A., Kaley G. (2004) PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 286, H742-H748.
5. Bastid C., Tellechea J., Sahel J. (1990) Does jaundice increase the frequency of gastroduodenal ulcerations? Hepatogastroenterology 37, 612-614.
6. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137, 354-366.
7. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. (2002) Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82, 615-624.
8. Brown J.F., Keates A.C., Hanson P.J., Whittle B.J. (1993) Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. Am. J. Physiol. 265, G418-G422.
9. Brzozowski T., Konturek P.C., Pajdo R. et al. (2005) Agonist of peroxisome proliferator-activated receptor gamma (PPAR-gamma): a new compound with potent gastroprotective and ulcer healing properties. Inflammopharmacology 13, 317-330.
10. Cameron G.R. & Oakley C.L. (1932) Ligation of the common bile duct. J. Pathol. Bacteriol. 35, 769-798.
11. Dehpour A.R., Mani A.R., Alikhani Z. et al. (1998) Enhancement of aspirin induced gastric damage by cholestasis in rats. Fundam. Clin. Pharmacol. 12, 442-445.
12. Dehpour A.R., Mani A.R., Amanlou M., Nahavandi A., Amanpour S., Bahadori M. (1999) Naloxone is protective against indomethacin-induced gastric damage in cholestatic rats. J. Gastroenterol. 34, 178-181.
13. Everett L., Galli A., Crabb D. (2000) The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 20, 191-199.
14. Feinstein D.L., Galea E., Gavrilyuk V. et al. (2002) Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann. Neurol. 51, 694-702.
15. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. (1995) 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83, 803-812.
16. Geraldo J., Ferraz P., Wallace J.L. (1996) Prostaglandins modulate the responsiveness of the gastric microcirculation of sodium nitroprusside in cirrhotic rats. Hepatology 23, 123-129.
17. Ghafourifar P., Dehpour A.R., Akbarloo N. (1997) Inhibition by L-NA, a nitric oxide synthase inhibitor, of naloxone-precipitated withdrawal signs in a mouse model of cholestasis. Life Sci. 60, PL 265-270.
18. Gyires K. (1994) The role of endogenous nitric oxide in the gastroprotective action of morphine. Eur. J. Pharmacol. 255, 33-37.
19. Hara N., Hara Y., Natsume Y., Goto Y. (1991) Gastric hyperacidity and mucosal damage caused by hypothermia correlate with increase in GABA concentrations of the rat brain. Eur. J. Pharmacol. 194, 77-81.
20. Heneka M.T., Klockgether T., Feinstein D.L. (2000) Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J. Neurosci. 20, 6862-6867.
21. Heneka M.T., Sastre M., Dumitrescu-Ozimek L. et al. (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128, 1442-1453.
22. Inan M., Sayek I., Tel B.C., Sahin-Erdemli I. (1997) Role of endotoxin and nitric oxide in the pathogenesis of renal failure in obstructive jaundice. Br. J. Surg. 84, 943-947.
23. Ito H., Asahi H., Horiuchi S. (1993) Role of oxygen radicals in the pathogenesis of acute gastric mucosal lesion under obstructive jaundice. Nihon Geka Gakkai Zasshi 94, 225-233.
24. Kitamura Y., Kakimura J., Matsuoka Y., Nomura Y., Gebicke-Haerter P.J., Taniguchi T. (1999) Activators of peroxisome proliferator-activated receptor-gamma (PPARgamma) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci. Lett. 262, 129-132.
25. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., Evans R.M. (1992) Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358, 771-774.
26. Kliewer S.A., Forman B.M., Blumberg B. et al. (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl Acad. Sci. USA 91, 7355-7359.
27. Konturek P.C., Brzozowski T., Kania J. et al. (2003a) Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat. Eur. J. Pharmacol. 472, 213-220.
28. Konturek P.C., Brzozowski T., Kania J. et al. (2003b) Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/reperfusion in rat. Scand. J. Gastroenterol. 38, 468-476.
29. Lahiri S., Sen T., Palit G. (2009) Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats. Eur. J. Pharmacol. 609, 118-125.
30. Ma L. & Wallace J.L. (2000) Endothelial nitric oxide synthase modulates gastric ulcer healing in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G341-G346.
31. Martinez-Cuesta M.A., Barrachina M.D., Pique J.M., Whittle B.J., Esplugues J.V. (1992) The role of nitric oxide and platelet-activating factor in the inhibition by endotoxin of pentagastrin-stimulated gastric acid secretion. Eur. J. Pharmacol. 218, 351-354.
32. Matsuo T., Sasaki I., Kamiyama Y. et al. (1989) Taurocholate-induced gastric damage in rats with obstructive jaundice. Scand. J. Gastroenterol. Suppl. 162, 83-86.
33. McIntyre R.S., Soczynska J.K., Lewis G.F., MacQueen G.M., Konarski J.Z., Kennedy S.H. (2006) Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Expert Opin. Pharmacother. 7, 1305-1321.
34. Moezi L., Heidari R., Amirghofran Z., Nekooeian A.A., Monabati A., Dehpour A.R. (2013) Enhanced anti-ulcer effect of pioglitazone on gastric ulcers in cirrhotic rats: the role of nitric oxide and IL-1beta. Pharmacol. Rep. 65, 134-143.
35. Nahavandi A., Dehpour A.R., Mani A.R., Homayounfar H., Abdoli A. (1999) N(G)-nitro-L-arginine methylester is protective against ethanol-induced gastric damage in cholestatic rats. Eur. J. Pharmacol. 370, 283-286.
36. Nahavandi A., Mani A.R., Homayounfar H., Akbari M.R., Dehpour A.R. (2001) The role of the interaction between endogenous opioids and nitric oxide in the pathophysiology of ethanol-induced gastric damage in cholestatic rats. Fundam. Clin. Pharmacol. 15, 181-187.
37. Nishida K., Ohta Y., Ishiguro I. (1997) Role of gastric mucosal constitutive and inducible nitric oxide synthases in the development of stress-induced gastric mucosal lesions in rats. Biochem. Biophys. Res. Commun. 236, 275-279.
38. Pereira M.P., Hurtado O., Cardenas A. et al. (2006) Rosiglitazone and 15-deoxy-Delta12, 14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J. Cereb. Blood Flow Metab. 26, 218-229.
39. Pique J.M., Whittle B.J., Esplugues J.V. (1989) The vasodilator role of endogenous nitric oxide in the rat gastric microcirculation. Eur. J. Pharmacol. 174, 293-296.
40. Plebani M., Panozzo M.P., Basso D., De Paoli M., Biasin R., Infantolino D. (1999) Cytokines and the progression of liver damage in experimental bile duct ligation. Clin. Exp. Pharmacol. Physiol. 26, 358-363.
41. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
42. Rocchi S. & Auwerx J. (1999) Peroxisome proliferator-activated receptor-gamma: a versatile metabolic regulator. Ann. Med. 31, 342-351.
43. Sasaki I., Miyakawa H., Kameyama J., Kamiyama Y., Sato T. (1986) Influence of obstructive jaundice on acute gastric ulcer, intragastric pH and potential difference in rats. Tohoku J. Exp. Med. 150, 161-168.
44. Schintu N., Frau L., Ibba M. et al. (2009) PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci. 29, 954-963.
45. Shian W.M., Sasaki I., Kamiyama Y. et al. (1994) Mucosal TBA reactants and glutathione levels in acute gastric mucosal injury in rats with obstructive jaundice. Ther. Res. 1, 77-83.
46. Sundararajan S., Gamboa J.L., Victor N.A., Wanderi E.W., Lust W.D., Landreth G.E. (2005) Peroxisome proliferator-activated receptor-gamma ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130, 685-696.
47. Takahashi S., Fujita T., Yamamoto A. (2001) Role of nuclear factor-kappaB in gastric ulcer healing in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G1296-G1304.
48. Tontonoz P., Hu E., Spiegelman B.M. (1995) Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor gamma. Curr. Opin. Genet. Dev. 5, 571-576.
49. Urakawa T., Nagahata Y., Nakamoto M., Kumagai K., Saitoh Y. (1987) An approach to the mechanism of acute ulceration in obstructive jaundice. Scand. J. Gastroenterol. 22, 634-640.